{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:45:34Z","timestamp":1793213134486,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ekir.2024.12.026","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T03:30:53Z","timestamp":1735615853000},"page":"743-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Vanja","family":"Ivkovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bruchfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McAdoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asheesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Kanzelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Touzot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Jaryal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Vikrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e4rbel","family":"Lange-Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Segelmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.12.026_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaut.2014.01.024","article-title":"Diagnosis and classification of Goodpasture\u2019s disease (anti-GBM)","volume":"48-49","author":"Hellmark","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2024.12.026_bib3","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ndt\/gfy327","article-title":"Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies","volume":"34","author":"Segelmark","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.026_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2024.12.026_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/pr.2017.315","article-title":"Management and outcomes of childhood Goodpasture\u2019s disease","volume":"83","author":"Menzi","year":"2018","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ekir.2024.12.026_bib6","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3389\/fimmu.2019.01665","article-title":"Prognostic factors in anti-glomerular basement membrane disease: A multicenter study of 119 patients","volume":"10","author":"Marques","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.12.026_bib7","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2024.12.026_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3899\/jrheum.181438","article-title":"Malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A population-based cohort study","volume":"47","author":"Heijl","year":"2020","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ekir.2024.12.026_bib9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2024.12.026_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40674-017-0082-y","article-title":"Avoidance of harm from treatment for ANCA-associated vasculitis","volume":"3","author":"King","year":"2017","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.ekir.2024.12.026_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000358887","article-title":"Update on rituximab: an established treatment for all immune-mediated kidney diseases?","volume":"126","author":"Evans","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.ekir.2024.12.026_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.026_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000535010","article-title":"Efficacy of rituximab for minimal change disease and focal segmental glomerulosclerosis with frequently relapsing or steroid-dependent nephrotic syndrome in adults: A Chinese multicenter retrospective study","volume":"55","author":"Lan","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.026_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ekir.2018.12.002","article-title":"Rituximab for anti-glomerular basement membrane disease","volume":"4","author":"Jain","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.026_bib16","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ndt\/gfad268","article-title":"Efficacy of rituximab for patients with anti-glomerular basement membrane disease","volume":"39","author":"Chen","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.026_bib17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.026_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1681\/ASN.2022050581","article-title":"Risk stratification to predict renal survival in anti-glomerular basement membrane disease","volume":"34","author":"Floyd","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2024.12.026_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2215\/CJN.04290417","article-title":"Predicting outcome in patients with anti-GBM glomerulonephritis","volume":"13","author":"van Daalen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ndt\/gfu399","article-title":"Predictors of renal and patient outcomes in anti-GBM disease: Clinicopathologic analysis of a two-centre cohort","volume":"30","author":"Alchi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.026_bib22","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1074\/jbc.271.15.9062","article-title":"The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3 (IV) chain of type IV collagen","volume":"271","author":"Kalluri","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2024.12.026_bib23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ki.1996.163","article-title":"Autoreactive T-cells in Goodpasture\u2019s syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen","volume":"49","author":"Merkel","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.026_bib24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1523-1755.1999.055003926.x","article-title":"Goodpasture antigen: Expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain","volume":"55","author":"Leinonen","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.026_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1523-1755.2000.00146.x","article-title":"High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen","volume":"58","author":"Rutgers","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.026_bib26","first-page":"789","article-title":"Relationship between anti-GBM antibodies and kidney outcomes in patients with anti-GBM disease","volume":"36","author":"Zhu","year":"2023","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1681\/ASN.2019060619","article-title":"Experimental antiglomerular basement membrane GN induced by a peptide from Actinomyces","volume":"31","author":"Gu","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti-glomerular basement membrane antibodies in\u00a0vivo in severe kidney disease: an open-label Phase 2a study","volume":"33","author":"Uhlin","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/gfad132","article-title":"Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment","volume":"39","author":"Tyrberg","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.026_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102885","article-title":"ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature","volume":"20","author":"Philip","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2024.12.026_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00467-021-05333-z","article-title":"Anti-glomerular basement membrane disease in children: A brief overview","volume":"37","author":"Dowsett","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10067-012-2062-9","article-title":"Characteristics and outcome of Goodpasture\u2019s disease in children","volume":"31","author":"Bayat","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2024.12.026_bib33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(83)90923-6","article-title":"Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane","volume":"2","author":"Donaghy","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.12.026_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0232-1513(88)80130-0","article-title":"The effect of oxygen toxicity and cigarette smoking on the binding of heterologous antibodies to alveolar basement membrane in the rat","volume":"33","author":"Rhodes","year":"1988","journal-title":"Exp Pathol"},{"key":"10.1016\/j.ekir.2024.12.026_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000060046","article-title":"Cigarette smoking and other inhaled toxins in anti-GBM disease","volume":"130","author":"H\u00e9rody","year":"2000","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","article-title":"Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome","volume":"37","author":"Chan","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","article-title":"Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature","volume":"30","author":"Kamei","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.026_bib38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study","volume":"33","author":"Chan","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.026_bib39","article-title":"Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)","volume":"8","author":"Uchida","year":"2024","journal-title":"Rheumatol Adv Pract"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924034661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924034661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:49:14Z","timestamp":1762627754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924034661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2468024924034661"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.026","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}